Acucela Inc. Presents Dry AMD Therapy Data at Association for Research in Vision & Ophthalmology
BOTHELL, Wash.--(BUSINESS WIRE)--Acucela presented new safety, tolerability and effectiveness data on ACU-4429, an investigational therapy for dry age-related macular degeneration (AMD), at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held this week in Fort Lauderdale, Florida.